Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- NBL +0.5% (Guidance update)
M&A news:
- GPC +9.9% (will acquire Alliance Automotive Group from Blackstone and AAG's co-founders)
Other news:
- ARDM +33.6% (FDA has accepted for filing with Priority Review its NDA for Linhaliq), ABUS +9.8% (announces topline results of the bi-weekly dosing segment of Cohort 4 of the Phase II study of its RNAi agent)CBIO +7.9% ( granted orphan designation by the FDA for Subcutaneous recombinant human factor IX variant with three point mutations for the treatment of Hemophilia B), SVA +7.1% (announces prelim top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Varicella vaccine against Chickenpox), NVCR +7% (reports Phase 3 data for combination of Optune with Temozolomide), AMRN +6.4% (Amarin and HLS Therapeutics announce agreement between the parties to register, commercialize and distribute Vascepa capsules in Canada),NLNK +6.3% (enters into a clinical collaboration agreement with AstraZeneca (AZN) to evaluate the combination of indoximod), BLDP+4.4% (announced that the U.S. Army Program Executive Office Soldier has received signature approval for its Mobile Soldier Power Program),CTSO +3.7% (highlights recent publication of a study entitled "Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study" in the Journal of Artificial Organ), EXEL +2.7% (reports ESAX-HTN pivotal study in essential hypertension met primary objective) GPRO +2.5% (Barron's profiles positive view on GoPro), PLUG +1.6% (in sympathy with BLDP),AGN +1.5% (Authorizes New $2 Billion Share Repurchase Program; reaffirms FY17 guidance), .
Analyst comments:
- RIG +4.5% (upgraded to Buy from Neutral at UBS)
- ESV +4% (upgraded to Buy from Neutral at UBS)
- AOBC +3.3% (upgraded to Outperform from Neutral at Wedbush)
- ROST +2.5% (upgraded to Overweight from Neutral at JP Morgan)
- BOX +1.7% (upgraded to Outperform from Mkt Perform at Raymond James)
- GM +1.6% (upgraded to Buy from Hold at Deutsche Bank)
- CMP +1.6% (upgraded to Overweight from Neutral at JP Morgan)
- UAA +0.9% (upgraded to Overweight from Sector Weight at KeyBanc Capital Mkts)
- CL +0.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)